Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Dec 3:e02639.
doi: 10.1002/cbdv.202502639. Online ahead of print.

Steroidal Scaffolds as Anticancer Agents: Evolution, FDA Approvals, Synthetic Derivatives, SAR Profiles, and Translational Perspectives

Prabhugouda Gugal  1 , Hemalatha Kamurthy  1 , Rohit Pal  1 , Gurubasavaraja Swamy P M  1 , Sanjay M  1 , Sowmya C M  1 , Koushik P M  1
Affiliations
Review

Steroidal Scaffolds as Anticancer Agents: Evolution, FDA Approvals, Synthetic Derivatives, SAR Profiles, and Translational Perspectives

Prabhugouda Gugal et al. Chem Biodivers. .

Abstract

Steroidal scaffolds, owing to their inherent structural rigidity, membrane permeability, and receptor affinity, have emerged as a critical class of molecules in anticancer drug development. This manuscript comprehensively explores the development, FDA-approved drugs such as dexamethasone, prednisone, and abiraterone acetate, synthetic innovations, and clinical potential of steroidal derivatives in anticancer therapy. Glucocorticoids and hormone modulators remain foundational in treating hematologic- and hormone-dependent cancers. At the same time, recent synthetic hybrids, including triazoles, isatins, pyrimidines, and benzisoselenazolones, have shown enhanced potency and selectivity across solid tumor models. The paper underscores the integration of steroids with potential anticancer activity, kinase inhibitors, and bioactive heterocycles to overcome pharmacokinetic limitations and hormone resistance. Several novel steroidal derivatives have demonstrated potent anticancer activity, as evidenced by low IC50 values: compound 29 (0.34 µM), 30 (0.25 µM and 0.28 µM), 32 (0.00083, 0.029, and 0.056 µM), and 36 (0.34 µM). These findings underscore their strong cytotoxic potential against cancer cell lines. The central perspective emphasizes the resurgence of steroid-based drug design in the precision medicine era, especially in the context of emerging synthetic strategies and their translational viability in resistant and metastatic cancer phenotypes. Furthermore, several investigational steroid-drug combinations are currently being evaluated in clinical trials for advanced-stage cancers, including prostate, breast, and head and neck malignancies, underscoring their translational potential. This review highlights both the therapeutic promise and future directions of steroidal anticancer agent, reinforcing their value as a cornerstone in the development of targeted and supportive cancer therapy.

Keywords: antitumor; cancer; chemotherapy; steroids; synthesis.

PubMed Disclaimer

References

    1. H. K. Weir, T. D. Thompson, S. L. Stewart, and M. C. White, “Cancer Incidence Projections in the United States Between 2015 and 2050,” Preventing Chronic Disease 18 (2021): E59, https://doi.org/10.5888/pcd18.210006.
    1. R. Pal, G. Teli, S. Sengupta, L. Maji, and G. S. Purawarga Matada, “An Outlook of Docking Analysis and Structure‐Activity Relationship of Pyrimidine‐Based Analogues as EGFR Inhibitors Against Non‐Small Cell Lung Cancer (NSCLC),” Journal of Biomolecular Structure and Dynamics 42, no. 18 (2024): 9795–9811, https://doi.org/10.1080/07391102.2023.2252082.
    1. S. Pilleron, E. Soto‐Perez‐De‐Celis, J. Vignat, et al., “Estimated Global Cancer Incidence in the Oldest Adults in 2018 and Projections to 2050,” International Journal of Cancer 148, no. 3 (2021): 601–608, https://doi.org/10.1002/ijc.33232.
    1. R. Pal, G. S. P. Matada, G. Teli, V. Chawla, and P. A. Chawla, “Design, Synthesis, and Biological Evaluation of Novel 4‐(4‐ethoxyphenyl)‐6‐(substituted‐phenyl) pyrimidin‐2‐amine/Thiol/Hydroxy Derivatives as EGFRWT and EGFRT790M Inhibitors Targeting NSCLC: In‐Vitro and In‐Silico Exploration,” Journal of Molecular Structure 1327 (2025): 141227, https://doi.org/10.1016/j.molstruc.2024.141227.
    1. G. Luo, Y. Zhang, J. Etxeberria, et al., “Projections of Lung Cancer Incidence by 2035 in 40 Countries Worldwide: Population‐Based Study,” JMIR Public Health and Surveillance 9, no. 1 (2023): e43651, https://doi.org/10.2196/43651.

LinkOut - more resources